Increased plasma S100A12 levels are associated with diabetic retinopathy and prognostic biomarkers of macrovascular events in type 2 diabetic patients

Investigative Ophthalmology and Visual Science

Volumn 56, Issue 8, 2015, Pages 4177-4185

  Dong, Ning ^a   Shi, Hong ^a   Xu, Bing ^a   Cai, Ying ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Biomarkers; Diabetes; Diabetic retinopathy; S100A12

Indexed keywords

ADVANCED GLYCATION END PRODUCT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CALCIUM BINDING PROTEIN; CREATININE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PENTOSIDINE; S100 CALCIUM BINDING PROTEIN A12; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; PROTEIN S 100; S100A12 PROTEIN, HUMAN;

AFFERENT PUPILLARY DEFECT; AGED; ANGIOGRAPHY; AREA UNDER THE CURVE; ARTICLE; BIOMICROSCOPY; BLOOD ANALYSIS; CONTROLLED STUDY; DIABETIC RETINOPATHY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; ELECTRORETINOGRAM; ENZYME LINKED IMMUNOSORBENT ASSAY; EYE EXAMINATION; EYE FUNDUS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SCORING SYSTEM; VISUAL ACUITY; BLOOD; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDY;

AGED; BIOLOGICAL MARKERS; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; FEMALE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; ROC CURVE; S100 PROTEINS;

EID: 84939641849     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.15-16470     Document Type: Article

References (40)

1. Jia WP, Pang C, Chen L, et al. Epidemiological characteristics of diabetes mellitus and impaired glucose regulation in a Chinese adult population: the Shanghai Diabetes Studies, a crosssectional 3-year follow-up study in Shanghai urban communities. Diabetologia. 2007;50:286–292
2. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047–1053
3. Ikram MK, Cheung CY, Lorenzi M, et al. Retinal vascular caliber as a biomarker for diabetes microvascular complications. Diabetes Care. 2013;36:750–759
4. Fong DS, Aiello L, Gardner TW, et al. Diabetic retinopathy. Diabetes Care. 2003;26:226–229
5. Schram MT, Chaturvedi N, Schalkwijk C, et al. Vascular risk factors and markers of endothelial function as determinants of inflammatory markers in type 1 diabetes: the EURODIAB Prospective Complications Study. Diabetes Care. 2003;26: 2165–2173
6. Adamis AP. Is diabetic retinopathy an inflammatory disease? Br J Ophthalmol. 2002;86:363–365
7. Krady JK, Basu A, Allen CM, et al. Minocycline reduces proinflammatory cytokine expression, microglial activation, and caspase-3 activation in a rodent model of diabetic retinopathy. Diabetes. 2005;54:1559–1565
8. Dong N, Li X, Xiao L, Yu W, Wang B, Chu L. Upregulation of retinal neuronal MCP-1 in the rodent model of diabetic retinopathy and its function in vitro. Invest Ophthalmol Vis Sci. 2012;53:7567–7575
9. Dong N, Xu B, Wang B, Chu L. Study of 27 aqueous humor cytokines in patients with type 2 diabetes with or without retinopathy. Mol Vis. 2013;19:1734–1746
10. Dong N, Chang L, Wang B, Chu L. Retinal neuronal MCP-1 induced by AGEs stimulates TNF-a expression in rat microglia via p38, ERK, and NF-jB pathways. Mol Vis. 2014;20:616–628
11. Nowak M, Wielkoszyński T, Marek B, et al. Antioxidant potential, paraoxonase 1, ceruloplasmin activity and Creactive protein concentration in diabetic retinopathy. Clin Exp Med. 2010;10:185–192
12. Klein BE, Knudtson MD, Tsai MY, Klein R. The relation of markers of inflammation and endothelial dysfunction to the prevalence and progression of diabetic retinopathy: Wisconsin epidemiologic study of diabetic retinopathy. Arch Ophthalmol. 2009;127:1175–1182
13. Nguyen TT, Alibrahim E, Islam FM, et al. Inflammatory, hemostatic, and other novel biomarkers for diabetic retinopathy: the multi-ethnic study of atherosclerosis. Diabetes Care. 2009;32:1704–1709
14. Takeuchi M, Yamagishi S. Involvement of toxic AGEs (TAGE) in the pathogenesis of diabetic vascular complications and Alzheimer’s disease. J Alzheimers Dis. 2009;16:845–858
15. Dyer DG, Blackledge JA, Thorpe SR, Baynes JW. Formation of pentosidine during nonenzymatic browning of proteins by glucose. Identification of glucose and other carbohydrates as possible precursors of pentosidine in vivo. J Biol Chem. 1991; 266:11654–11660
16. Odetti P, Fogarty J, Sell DR, Monnier VM. Chromatographic quantitation of plasma and erythrocyte pentosidine in diabetic and uremic subjects. Diabetes. 1992;41:153–159
17. Santos AR, Dvoriantchikova G, Li Y, et al. Cellular mechanisms of high mobility group 1 (HMGB-1) protein action in the diabetic retinopathy. PLoS One. 2014;9:e87574
18. Kosaki A, Hasegawa T, Kimura T, et al. Increased plasma S100A12 (EN-RAGE) levels in patients with type 2 diabetes. J Clin Endocrinol Metab. 2004;89:5423–5428
19. Pradeep AR, Martande SS, Singh SP, Suke DK, Raju AP, Naik SB. Correlation of human S100A12 (EN-RAGE) and high-sensitivity C-reactive protein as gingival crevicular fluid and serum markers of inflammation in chronic periodontitis and type 2 diabetes. Inflamm Res. 2014;63:317–323
20. Grossin N, Wautier MP, Meas T, Guillausseau PJ, Massin P, Wautier JL. Severity of diabetic microvascular complications is associated with a low soluble RAGE level. Diabetes Metab. 2008;34:392–395
21. Sarangi R, Padhi S, Mohapatra S, et al. Serum high sensitivity Creactive protein, nitric oxide metabolites, plasma fibrinogen, and lipid parameters in Indian type 2 diabetic males. Diabetes Metab Syndr. 2012;6:9–14
22. Fronczyk A, Moleda P, Safranow K, Piechota W, Majkowska L. Increased concentration of C-reactive protein in obese patients with type 2 diabetes is associated with obesity and presence of diabetes but not with macrovascular and microvascular complications or glycemic control. Inflammation. 2014;37:349–357
23. Tan KC, Chow WS, Tam S, Bucala R, Betteridge J. Association between acute-phase reactants and advanced glycation end products in type 2 diabetes. Diabetes Care. 2004;27:223–228
24. Ono Y, Aoki S, Ohnishi K, Yasuda T, Kawano K, Tsukada Y. Increased serum levels of advanced glycation end-products and diabetic complications. Diabetes Res Clin Pract. 1998;41: 131–137
25. Kerkeni M, Saïdi A, Bouzidi H, Ben Yahya S, Hammami M. Elevated serum levels of AGEs, sRAGE, and pentosidine in Tunisian patients with severity of diabetic retinopathy. Microvasc Res. 2012;84:378–383
26. Kerkeni M, Saïdi A, Bouzidi H, Letaief A, Ben Yahia S, Hammami M. Pentosidine as a biomarker for microvascular complications in type 2 diabetic patients. Diab Vasc Dis Res. 2013;10:239–245
27. Goldin A, Beckman JA, Schmidt AM, Creager MA. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation. 2006;114:597–605
28. Sugiyama S, Miyata T, Ueda Y, et al. Plasma levels of pentosidine in diabetic patients: an advanced glycation end product. J Am Soc Nephrol. 1998;9:1681–1688
29. Ng ZX, Chua KH, Iqbal T, Kuppusamy UR. Soluble receptor for advanced glycation end-product (sRAGE)/pentosidine ratio: a potential risk factor determinant for type 2 diabetic retinopathy. Int J Mol Sci. 2013;14:7480–7491
30. Kajikawa M, Nakashima A, Fujimura N, et al. Ratio of serum levels of AGEs to soluble form of RAGE is a predictor of endothelial function. Diabetes Care. 2015;38:119–125
31. Yamagishi S, Matsui T. Soluble form of a receptor for advanced glycation end products (sRAGE) as a biomarker. Front Biosci (Elite Ed). 2010;2:1184–1195
32. Nin JW, Jorsal A, Ferreira I, et al. Higher plasma soluble receptor for advanced glycation end products (sRAGE) levels are associated with incident cardiovascular disease and allcause mortality in type 1 diabetes: a 12-year follow-up study. Diabetes. 2010;59:2027–2032
33. Fujisawa K, Katakami N, Kaneto H, et al. Circulating soluble RAGE as a predictive biomarker of cardiovascular event risk in patients with type 2 diabetes. Atherosclerosis. 2013;227:425–428
34. Pietzsch J, Hoppmann S. Human S100A12: a novel key player in inflammation? Amino Acids. 2009;36:381–389
35. Woo SJ, Ahn SJ, Ahn J, Park KH, Lee K. Elevated systemic neutrophil count in diabetic retinopathy and diabetes: a hospital-based cross-sectional study of 30,793 Korean subjects. Invest Ophthalmol Vis Sci. 2011;52:7697–7703
36. Kim SY, Johnson MA, McLeod DS, Alexander T, Hansen BC, Lutty GA. Neutrophils are associated with capillary closure in spontaneously diabetic monkey retinas. Diabetes. 2005;54: 1534–1542
37. Guignard F, Mauel J, Markert M. Identification and characterization of a novel human neutrophil protein related to the S100 family. Biochem J. 1995;309:395–401
38. Yao D, Brownlee M. Hyperglycemia-induced reactive oxygen species increase expression of the receptor for advanced glycation end products (RAGE) and RAGE ligands. Diabetes. 2010;59:249–255
39. Schofield ZV, Woodruff TM, Halai R, Wu MC, Cooper MA. Neutrophils-a key component of ischemia-reperfusion injury. Shock. 2013;40:463–470
40. Wakisaka Y, Ago T, Kamouchi M, et al. Plasma S100A12 is associated with functional outcome after ischemic stroke: research for biomarkers in ischemic stroke. J Neurol Sci. 2014; 340:75–79.